axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • MSC 2.0
INNOVAC PPR
13 October 2019
3D-CELLS
13 October 2019

MSC 2.0

MSC 2.0

Improved cellular therapy product to protect the myocardia from post-infarction remodeling

Available technology

Desired partnership(s)

  • Licensing

IP

  • Know-how

Establishment(s)

  • University of Montpellier
  • Inserm
  • CNRS

Laboratory(ies)

  • IRMB (Institute for Regenerative Medicine & Biotherapy) - U1183
  • IGF (Institute of Functional Genomics) - UMR5203 / U1191

Keywords

  • Myocardial infarction
  • Human mesenchymal stem cells
  • Innovative cell therapy

Context

Cardiovascular diseases, including myocardial infarction (MI), are the leading cause of death worldwide. Myocardial reperfusion by reopening the blocked artery is helpful but it leads to ischemia-reperfusion (IR) damage. Mesenchymal stem cells (MSCs) are an excellent potential candidate for MI therapy as they are both immunomodulating and regenerative. While pre-clinical studies have been positive, Phase III trials remain inconclusive, notably due to the phenotypic and functional versatility of MSCs, as well as varying storage conditions and injected doses.

Benefits

This project has developed innovative cell therapy based on the use of improved allogeneic human MSCs, pre-treating them with a chemical molecule that maximizes their effects once they are injected. The “super-active” MSCs can be used at low dosage levels, regardless of the therapeutic window and storage conditions. This breakthrough strategy will enable the development of a cell therapy product for all patients with myocardial infarction that leads to heart failure.

Applications

Myocardial infarction, post-infarction remodeling

AVAILABLE TECHNOLOGY | Myocardial infarction – Human mesenchymal stem cells – Innovative cell therapy

Share
1

Related posts

8 September 2021

StabCFTR


En savoir +
6 July 2021

HTLV-1


En savoir +
23 June 2021

GEOSOTECH


En savoir +
© 2023, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French